Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration. MDR-001 is for the treatment of indications such as obesity and type 2 diabetes. Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development. Medicilon GLP-1 New Drug R&D Services One-stop support for new drug development and innovation From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention. As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug disco...